Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (NCT03439865) | Clinical Trial Compass
RecruitingEarly Phase 1
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis
United States20 participantsStarted 2019-05-02
Plain-language summary
The purpose of this pilot study is to explore wither ivacaftor in refractory CRS patients will demonstrate safety and tolerability; restore CFTR-mediated Cl- secretions as measured by EDSPD testing; produce detectable improvements in validated measures of CRS including the SNOT-22 questionnaire, Lund-MacKay CT scan grading, and Lund-Kennedy endoscopic scores; and provide beneficial effects on readily measured markers of sinonasal inflammation and infection (IP-10, IL-8, and Pseudomonas CFUs).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 18 years of age
* Patient has provided informed consent
* Diagnosis of CRS made by one of the investigators
* Standard of care CT scan with definitive demonstration of isolated or diffuse mucosal thickening, bone changes, and air fluid levels, obtained within 30 days of treatment
* Positive culture of at least one gram negative bacteria (e.g. Pseudomonas, E. coli, Steenotrophomonas) within 30 days prior to testing
* Previous surgery with (at least) exposed maxillary and ethmoid sinuses
* Ability to perform EDSPD testing such that nasal cavity space and sinus openings are sufficient for catheter placement
* Negative pregnancy test for females of childbearing potential within 72 hours of testing and start of study treatment
Exclusion Criteria:
* \< 18 years of age
* Acute illness other than sinusitis within 2 weeks before start of study treatment that, in the opinion of the investigator, would preclude participation
* Currently taking medications that are moderate or strong CP3A inhibitors
* History of asthma attack requiring emergency room visit or treatment with oral steroids within 2 months prior to study treatment
* History of solid organ or hematological transplantation
* History of known immunodeficiency, autoimmune or granulomatous disorder
* Serum creatinine \> 1.5x upper normal limit
* Abnormal liver function, as defined by serum AST \> 2x upper normal limit, serum ALT \> 2x upper normal limit, Alkaline phosphatase \> 2x upper normal limit, Tot…